234 related articles for article (PubMed ID: 16441227)
1. Targeting chaperones in transformed systems--a focus on Hsp90 and cancer.
Chiosis G
Expert Opin Ther Targets; 2006 Feb; 10(1):37-50. PubMed ID: 16441227
[TBL] [Abstract][Full Text] [Related]
2. Targeting HSP90 for cancer therapy.
Mahalingam D; Swords R; Carew JS; Nawrocki ST; Bhalla K; Giles FJ
Br J Cancer; 2009 May; 100(10):1523-9. PubMed ID: 19401686
[TBL] [Abstract][Full Text] [Related]
3. The Hsp90 chaperone as a promising drug target.
Piper PW
Curr Opin Investig Drugs; 2001 Nov; 2(11):1606-10. PubMed ID: 11763165
[TBL] [Abstract][Full Text] [Related]
4. [Hsp90--a target for anticancer therapy].
Růcková E; Müller P; Vojtesek B
Klin Onkol; 2011; 24(5):329-37. PubMed ID: 22070013
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
Workman P
Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HSP90 molecular chaperones: moving into the clinic.
Garcia-Carbonero R; Carnero A; Paz-Ares L
Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic target Hsp90 and cancer hallmarks.
Miyata Y; Nakamoto H; Neckers L
Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
[TBL] [Abstract][Full Text] [Related]
8. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
9. Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.
Shevtsov M; Multhoff G; Mikhaylova E; Shibata A; Guzhova I; Margulis B
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31652993
[TBL] [Abstract][Full Text] [Related]
10. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
11. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
12. The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.
Woodford MR; Dunn DM; Blanden AR; Capriotti D; Loiselle D; Prodromou C; Panaretou B; Hughes PF; Smith A; Ackerman W; Haystead TA; Loh SN; Bourboulia D; Schmidt LS; Marston Linehan W; Bratslavsky G; Mollapour M
Nat Commun; 2016 Jun; 7():12037. PubMed ID: 27353360
[TBL] [Abstract][Full Text] [Related]
13. Macrocyclic inhibitors of hsp90.
Johnson VA; Singh EK; Nazarova LA; Alexander LD; McAlpine SR
Curr Top Med Chem; 2010; 10(14):1380-402. PubMed ID: 20536417
[TBL] [Abstract][Full Text] [Related]
14. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
15. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
Tsutsumi S; Neckers L
Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
[TBL] [Abstract][Full Text] [Related]
16. Emerging Hsp90 inhibitors: from discovery to clinic.
Chiosis G; Rodina A; Moulick K
Anticancer Agents Med Chem; 2006 Jan; 6(1):1-8. PubMed ID: 16475922
[TBL] [Abstract][Full Text] [Related]
17. Overview: translating Hsp90 biology into Hsp90 drugs.
Workman P
Curr Cancer Drug Targets; 2003 Oct; 3(5):297-300. PubMed ID: 14529382
[TBL] [Abstract][Full Text] [Related]
18. Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone.
Singh JK; Hutt DM; Tait B; Guy NC; Sivils JC; Ortiz NR; Payan AN; Komaragiri SK; Owens JJ; Culbertson D; Blair LJ; Dickey C; Kuo SY; Finley D; Dyson HJ; Cox MB; Chaudhary J; Gestwicki JE; Balch WE
Cell Chem Biol; 2020 Mar; 27(3):292-305.e6. PubMed ID: 32017918
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
Workman P
Cancer Lett; 2004 Apr; 206(2):149-57. PubMed ID: 15013520
[TBL] [Abstract][Full Text] [Related]
20. Targeting Hsp90 for the treatment of cancer.
Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
